Acute Ischemic Stroke is an indication for drug development with over 100 pipeline drugs currently active. According to GlobalData, preregistered drugs for Acute Ischemic Stroke have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Acute Ischemic Stroke compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Acute Ischemic Stroke overview

Acute ischemic stroke occurs when a clot blocks a brain blood vessel, depriving it of oxygen. Symptoms, like numbness, confusion, or difficulty speaking, arise suddenly. Immediate medical attention is crucial. Treatment focuses on restoring blood flow, often with clot-dissolving drugs or a thrombectomy. Recovery varies; rehabilitation helps regain lost abilities. Lifestyle changes and medication may prevent future strokes. Early recognition and swift intervention significantly improve recovery chances, emphasizing the importance of prompt action at the first signs of a stroke.

For a complete picture of PTSR and LoA scores for drugs in Acute Ischemic Stroke, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.